InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.390 -0.045 (-10.34%)+
Announcement
Release
5 Jan 2026 8:41AM
Price at Release
$0.435
Full Release
download
Summary
Island Pharmaceuticals Limited has provided an update on their ongoing discussions with the US FDA regarding the clinical development of Galidesivir. The FDA is reviewing Island’s recent submission concerning Galidesivir's development pathway under the FDA's Animal Rule. The FDA has confirmed Galidesivir's eligibility for approval under this pathway and possible Priority Review Voucher status. The FDA hasn't requested additional data or changed its previous stance, indicating a positive engagement. Island is advancing preparatory activities, including discussions for conducting non-human primate studies and engaging with US Government stakeholders. CEO Dr. David Foster highlighted the constructive nature of the ongoing regulatory process with the FDA, emphasizing the importance of the guidance being sought.
Key Points
  • Ongoing engagement with the US FDA for Galidesivir's clinical development.
  • FDA requires additional time for review but hasn't requested more data or changed its guidance.
  • Galidesivir eligible for approval under the Animal Rule and Priority Review Voucher status.
  • Island Pharmaceuticals is advancing study preparations and engaging with potential study partners.
  • CEO Dr. David Foster sees the review process as constructive and important for Galidesivir's development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.